These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 30748089)
21. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089 [TBL] [Abstract][Full Text] [Related]
22. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR). Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270 [TBL] [Abstract][Full Text] [Related]
23. Does tubulitis without interstitial inflammation represent borderline acute T cell mediated rejection? Nankivell BJ; P'Ng CH; Chapman JR Am J Transplant; 2019 Jan; 19(1):132-144. PubMed ID: 29687946 [TBL] [Abstract][Full Text] [Related]
24. Impact of the immunotherapy induction on allograft outcome and survival in kidney transplant patients with donor-specific antibodies to HLA-DQB1. Dutra RS; Fabreti-Oliveira RA; Lasmar MF; Araujo SA; Nascimento E Transpl Immunol; 2021 Jun; 66():101390. PubMed ID: 33838296 [TBL] [Abstract][Full Text] [Related]
25. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss. Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275 [TBL] [Abstract][Full Text] [Related]
26. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. Viglietti D; Loupy A; Aubert O; Bestard O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Jouven X; Delahousse M; Kamar N; Lefaucheur C J Am Soc Nephrol; 2018 Feb; 29(2):606-619. PubMed ID: 29255058 [TBL] [Abstract][Full Text] [Related]
27. Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants. Halloran PF; Merino Lopez M; Barreto Pereira A Am J Transplant; 2016 Mar; 16(3):908-20. PubMed ID: 26743766 [TBL] [Abstract][Full Text] [Related]
28. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study. Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765 [TBL] [Abstract][Full Text] [Related]
29. Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation. Senev A; Van Loon E; Lerut E; Coemans M; Callemeyn J; Daniëls L; Kerkhofs J; Koshy P; Kuypers D; Lamarthée B; Sprangers B; Tinel C; Van Craenenbroeck AH; Van Sandt V; Emonds MP; Naesens M Am J Kidney Dis; 2022 Dec; 80(6):718-729.e1. PubMed ID: 35690154 [TBL] [Abstract][Full Text] [Related]
30. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Matignon M; Muthukumar T; Seshan SV; Suthanthiran M; Hartono C Transplantation; 2012 Sep; 94(6):603-11. PubMed ID: 22932115 [TBL] [Abstract][Full Text] [Related]
31. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597 [TBL] [Abstract][Full Text] [Related]
32. Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. Callemeyn J; Lerut E; de Loor H; Arijs I; Thaunat O; Koenig A; Meas-Yedid V; Olivo-Marin JC; Halloran P; Chang J; Thorrez L; Kuypers D; Sprangers B; Van Lommel L; Schuit F; Essig M; Gwinner W; Anglicheau D; Marquet P; Naesens M J Am Soc Nephrol; 2020 Sep; 31(9):2168-2183. PubMed ID: 32641395 [TBL] [Abstract][Full Text] [Related]
33. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients. Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243 [TBL] [Abstract][Full Text] [Related]
34. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss. Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905 [TBL] [Abstract][Full Text] [Related]
35. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus. Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172 [TBL] [Abstract][Full Text] [Related]
36. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Haas M; Loupy A; Lefaucheur C; Roufosse C; Glotz D; Seron D; Nankivell BJ; Halloran PF; Colvin RB; Akalin E; Alachkar N; Bagnasco S; Bouatou Y; Becker JU; Cornell LD; Duong van Huyen JP; Gibson IW; Kraus ES; Mannon RB; Naesens M; Nickeleit V; Nickerson P; Segev DL; Singh HK; Stegall M; Randhawa P; Racusen L; Solez K; Mengel M Am J Transplant; 2018 Feb; 18(2):293-307. PubMed ID: 29243394 [TBL] [Abstract][Full Text] [Related]
37. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients. Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484 [TBL] [Abstract][Full Text] [Related]
38. Utility of protocol kidney biopsies for de novo donor-specific antibodies. Parajuli S; Reville PK; Ellis TM; Djamali A; Mandelbrot DA Am J Transplant; 2017 Dec; 17(12):3210-3218. PubMed ID: 28805293 [TBL] [Abstract][Full Text] [Related]
39. FOXP3 mRNA Profile Prognostic of Acute T Cell-mediated Rejection and Human Kidney Allograft Survival. Luan D; Dadhania DM; Ding R; Muthukumar T; Lubetzky M; Lee JR; Sharma VK; August P; Mueller FB; Schwartz JE; Suthanthiran M Transplantation; 2021 Aug; 105(8):1825-1839. PubMed ID: 33031221 [TBL] [Abstract][Full Text] [Related]
40. Differences in Pathologic Features and Graft Outcomes of Rejection on Kidney Transplant. Park WY; Paek JH; Jin K; Park SB; Choe M; Han S Transplant Proc; 2019 Oct; 51(8):2655-2659. PubMed ID: 31345597 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]